Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to Steffers0,Anonymous,CryptoPlankton,GrahamPlatt,Walkeia, for Donating to support the site

GlaxoSmithkline Final Results

Practical discussions about equity High-Yield Portfolios (HYP) for income
Forum rules
Tight HYP discussions only please - OT please discuss in strategies
idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

GlaxoSmithkline Final Results

#199277

Postby idpickering » February 6th, 2019, 12:08 pm


·

Group sales £30.8 billion, +2% AER, +5% CER


·

Pharmaceuticals sales £17.3 billion, flat AER, +2% CER; Vaccines sales £5.9 billion, +14% AER, +16% CER; Consumer Healthcare sales £7.7 billion, -1% AER, +2% CER


·

Total new Respiratory product sales £2.6 billion, +35% AER, +38% CER


·

Total HIV sales £4.7 billion, +9% AER, +11% CER. Dolutegravir-based regimens £4.4 billion, +14% AER, +16% CER


·

Shingrix sales £784 million, +>100% AER, +>100% CER


·

Total Group operating margin 17.8%, +4.3 percentage points AER, +5.0 percentage points CER


·

Adjusted Group operating margin 28.4%, flat AER, +0.5 percentage points CER. (Pharmaceuticals: 33.3%; Vaccines 33.0%; Consumer Healthcare 19.8%)


·

Total EPS 73.7p, +>100% AER, +>100% CER, reflecting stronger operating performance, lower restructuring and impairment charges as well as a favourable comparison with impact of US tax reform in 2017


·

Adjusted EPS 119.4p, +7% AER, +12% CER, driven by improved operating margin and continued financial efficiencies


·

Net cash flow from operations £8.4 billion. Free cash flow £5.7 billion, improvement reflecting greater focus on cash conversion, particularly working capital


·

23p dividend declared for the quarter; 80p for full year 2018


·

4 major transactions, including new Consumer Healthcare JV, announced in 2018 to support strategy and reshape of the Group's portfolio

And later;

Quarterly dividends

The Board has declared a fourth interim dividend for 2018 of 23 pence per share (Q4 2017: 23 pence per share).



GSK recognises the importance of dividends to shareholders and aims to distribute regular dividend payments that will be determined primarily with reference to the free cash flow generated by the business after funding the investment necessary to support the Group's future growth.



The Board intends to maintain the dividend for 2019 at the current level of 80p per share, subject to any material change in the external environment or performance expectations. Over time, as free cash flow strengthens, it intends to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x, before returning the dividend to growth.



Payment of dividends

The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 9 April 2019. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) (2018: $0.02 per ADS; $0.005 per ADS per quarter) is charged by the Depositary.



The ex-dividend date will be 21 February 2019, with a record date of 22 February 2019 and a payment date of 11 April 2019.



https://www.investegate.co.uk/glaxosmit ... 01232693P/

kempiejon
Lemon Quarter
Posts: 1158
Joined: November 5th, 2016, 10:30 am
Has thanked: 5 times
Been thanked: 247 times

Re: GlaxoSmithkline Final Results

#199288

Postby kempiejon » February 6th, 2019, 12:37 pm

So with a yield of about 5.25%, static for the last 4 years and static for the next period and improving cover before increasing income this sounds a lot like AstraZennca with there 7 years static except GSK will start you at 5.25% whereas AZN only 3.79%.
I use current yields from https://www.dividenddata.co.uk/dividend ... y?epic=AZN

idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithkline Final Results

#199289

Postby idpickering » February 6th, 2019, 12:41 pm

I hold both of the pharmas, and have no intention of buying more of either any time soon, as I have full holdings already. The yields on offer are fine by me, and I shall continue to hold.

Ian.

maximan
2 Lemon pips
Posts: 165
Joined: November 4th, 2016, 3:41 pm
Has thanked: 222 times
Been thanked: 52 times

Re: GlaxoSmithkline Final Results

#199295

Postby maximan » February 6th, 2019, 1:10 pm

Thanks Ian.
Well at least the dividend will be held even though Adjusted EPS is due to decline in 2019 by between 5 to 9%.
The market likes them from a low of 1476.8 to a high of 1539.8.


Return to “High Yield Portfolios (HYP) - Practical”

Who is online

Users browsing this forum: No registered users and 17 guests